Using nanotechnology to catch and identify ErbB2/Her2 positive cancers

What is it about?

Early & accurate diagnosis of cancers are critical factors for determining the outcome of most cancer treatments. In the clinic, molecular tools (e.g. immunohistochemistry and ELISA) are used to characterise cancer subtypes and guide therapy. However, these approaches, whilst useful, can fall short in terms of sensitivity, accuracy, speed & subjectivity. This publication looks at novel in vitro and in vivo nanomaterial-based toolkits which aim to greatly improve the quality of cancer diagnosis

Featured Image

Why is it important?

This publication illustrates the current state of clinical diagnostics used in detection and quantification of ErbB2/Her2-positive cancers, and shows the emerging nanotechnological approaches being developed to improve the state of cancer detection.